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Abstract
Background: At the beginning of neurogenesis, massive brain cell death occurs and more than 50% of cells are
eliminated by apoptosis along with neuronal differentiation. However, few studies were conducted so far regarding
the regulation of neural progenitor cells (NPCs) death during development. Because of the physiological role of cell
death during development, aberration of normal apoptotic cell death is detrimental to normal organogenesis.
Apoptosis occurs in not only neuron but also in NPCs and neuroblast. When growth and survival signals such as
EGF or LIF are removed, apoptosis is activated as well as the induction of differentiation. To investigate the
regulation of cell death during developmental stage, it is essential to investigate the regulation of apoptosis of
NPCs.
Methods: Neural progenitor cells were cultured from E14 embryonic brains of Sprague-Dawley rats. For in vivo VPA
animal model, pregnant rats were treated with VPA (400 mg/kg S.C.) diluted with normal saline at E12. To analyze
the cell death, we performed PI staining and PARP and caspase-3 cleavage assay. Expression level of proteins was
investigated by Western blot and immunocytochemical assays. The level of mRNA expression was investigated by
RT-PCR. Interaction of Bcl-XL gene promoter and NF-B p65 was investigated by ChIP assay.
Results: In this study, FACS analysis, PI staining and PARP and caspase-3 cleavage assay showed that VPA protects
cultured NPCs from cell death after growth factor withdrawal both in basal and staurosporine- or hydrogen
peroxide-stimulated conditions. The protective effect of prenatally injected VPA was also observed in E16
embryonic brain. Treatment of VPA decreased the level of IBa and increased the nuclear translocation of NF-B,
which subsequently enhanced expression of anti-apoptotic protein Bcl-XL.
Conclusion: To the best of our knowledge, this is the first report to indicate the reduced death of NPCs by VPA at
developmentally critical periods through the degradation of IBa and the activation of NF-B signaling. The
reduced NPCs death might underlie the neurodevelopmental defects collectively called fetal valproate syndrome,
which shows symptoms such as mental retardation and autism-like behavior.
Background
The importance of cell death for normal brain morpho-
genesis in the developing nervous system has been
acknowledged since the beginning of modern neu-
roscience era [1,2]. Programmed cell death is a normal
and physiological process to allow proper development
of structure and function. In nervous system, more than
half of the neurons die via apoptotic cell death during
the developmental course [3-6].
At the level of the individual cell, apoptosis is trig-
gered by a wide spectrum of stimuli during embryonic
development, not only in response to stress and disease
but also as a part of normal tissue homeostasis [3].
Because of the physiological role of cell death during
development, aberration of normal apoptotic cell death
is detrimental to normal organogenesis. Excessive cell
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any medium, provided the original work is properly cited.death can result in functional deficits from the loss of
specific cell populations, which occurs during age-asso-
ciated neurodegenerative disorders [7,8], while reduced
cell death may results in overgrowth and functional dis-
organization of the organ. In peripheral system, the loss
of cells during development regulates sculpting digits,
removing a tail, or eliminating lymphocytes of unwanted
specificities [9]. Although the reduced neuronal death is
not considered detrimental in vertebrates in the labora-
tory environment, reduced neuronal death in vivo may
alter functional and structural properties of nervous sys-
tems leading to the developmental disorders with abnor-
mal brain function.
Apoptosis occurs in not only neuron but also in NPCs
and neuroblast [10-12]. When growth and survival sig-
nals such as EGF or LIF are removed, apoptosis is acti-
vated concomitant with the induction of differentiation
[13,14]. To investigate the regulation of cell death dur-
ing developmental stage, it is essential to investigate the
regulation of apoptosis of NPCs.
Valproic acid (VPA), discovered as an anti-convulsant
drug and is also used as the anti-bipolar disorder drug,
regulates several signaling pathways in brain cells. VPA
inhibits class I and II HDACs. In vitro studies showed
that VPA specifically triggers phosphorylation of ERK,
the upstream modulator of AP-1, without alteration of
JNK and p38 pathways [15]. It also inhibits GSK-3b-
mediated phosphorylation of proteins including b-cate-
nin. In addition, VPA has been implicated in the regula-
tion of LOX, PPARs, PTEN pathways [16]. Through the
regulation of the above mentioned pathways, VPA has
been generally considered to be neuroprotective.
Of interest is the recent reports suggesting the up-
regulation of the cytoprotective protein Bcl-2 by VPA
in neuron [17]. As we reported previously, VPA
induces developmental defects when administered at
developmentally critical periods [18], which includes
functional deficits including mental retardation as well
as structural abnormalities such as neural tube defects
and the overgrowth of brain. In this study, we investi-
gated whether VPA protects NPCs from cell death and
if so, the mechanism by which VPA mediates the
effects.
Materials and methods
Materials
Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12),
B27-serum free supplement and antibiotics were
obtained from Gibco BRL (Gland Island, NY, USA).
VPA, EGF, poly-L-ornithine and staurosporine were
purchased from Sigma (St. Louis, MO). FGF was
obtained from Invitrogen (Carlsbad, CA). H2O2 was pur-
chased from Merck (Darmstadt, Germany). NF-Bi n h i -
bitor 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
(TDZD-8) was obtained from Calbiochem-Novabiochem
(San Diego, CA).
Animals
Sprague Dawley (SD) rats were used throughout this
study. Pregnant rats were injected with VPA or normal
saline at E12 and brain tissues were dissected out from
E14 and E16 embryos. Animal handling was in accor-
dance with national guidelines and approved by the
‘Seoul National University Institutional Animal Care and
Use Committee (SNUIACUC)’.
Neural progenitor cell culture
The preparation of cortical progenitors from embryos
was based on the method previously described and
slightly modified by us [19,20]. NPCs were prepared
from E14 embryos of SD rats. Cortices were dissociated
into single cells by mechanical trituration and the cells
were incubated with Dulbecco’s modified Eagle’sm e d -
ium/F12 (DMEM/F12) supplemented with B27-serum
free supplement, 20 ng/ml EGF and 10 ng/ml FGF in a
5% CO2 incubator. EGF and FGF were added every day
and the cells grew into floating neurospheres. The pri-
mary neurosphere was dissociated into single cells with
trypsin-EDTA (GibcoBRL, a subsidiary of Invitrogen,
Carlsbad, CA) and the cells were incubated as neuro-
spheres in EGF and FGF containing media. This proce-
dure was repeated and neurosphere colonies were again
dissociated into single cells and plated on poly-L-
ornithine coated plates with DMEM/F12 media contain-
ing 20 ng/ml EGF. The purity of culture was checked by
immunostaining using an antibody against nestin, which
is a marker for NPCs. In this study, 95% of cells were
positive to nestin. Next day, the media was removed and
NPCs were incubated with fresh growth factor-free
media. One hour later, reagents were treated to NPCs
culture. Protein samples were harvested 8 hours after
VPA treatment for Western blot. Samples were fixed
with 4% PFA 8 hours after VPA treatment for immuno-
cytochemistry. For RT-PCR analysis, cellular RNA was
harvested 2 hours after VPA treatment.
Preparation of whole brain lysate
Whole brains were taken from embryonic day 14 and 16
animals. For the Western blot and RT-PCR, homoge-
nized brain tissues were prepared in lysis buffer and Tri-
zol respectively. Lysates were diluted by 2X sample
buffer and adjusted to 1 μg/μl concentration of protein
after the BCA protein assay.
FACS analysis
NPCs dissociated into single cells were used to detect
ratio of dead cells by FACS analysis. Approximately 1 ×
10
6 cells were used for each analysis. NPCs were
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Page 2 of 13trypsinized and PBS containing 1% FBS was added. After
PBS washing, cells were resuspended in PBS containing
1% FBS and 0.5 μg/ml propidium iodide (PI). The cell
suspension was kept for 5 min at room temperature,
and then ratios of positive or negative PI signal were
measured by flow cytometry (FACS Calibur System, BD
Biosciences, San Jose, CA). The experimental data were
analyzed using CellQuest software.
Western blot
NPCs were treated with VPA and 8 hours later, cells
were washed with PBS and harvested with lysis buffer.
Separation of protein bands was performed by 10 or
15% SDS-polyacrylamide gel electrophoresis and pro-
teins were electrically transferred onto nitrocellulose
(NC) membranes. The membranes were blocked with
polyvinyl alcohol diluted in DDW (10 μg/ml). Mem-
branes were then incubated overnight with the PARP-1
(1:5000, Santa Cruz, CA) and caspase-3 (1:5000, Cell
Signaling, Danvers, MA) antibody, which were used as a
marker for cell death. Other antibodies used in this
study include NF-B p65, NF-B p50, Bcl-XL, Bax
(1:5000, Santa Cruz, CA), IBa (1:5000, Cell Signaling,
Danvers, MA) and b-actin (1:10000, Sigma, St. Louis,
MO). We used NUP98 (1:5000, Cell Signaling, Danvers,
MA), which located at nuclear complex [21], as nuclear
marker. As a cytoplasmic marker, a-tubulin (1:5000,
Abcam, Cambridge, UK) was used. Membranes were
washed 3 times with PBS-Tween (0.2% tween-20) for 10
min each, followed by incubation with horse-radish per-
oxidase-conjugated secondary antibody for 2 hours at
room temperature. The membranes were developed
with enhanced chemiluminescence (ECL) solution
(Millipore, Billerica, MA) according to manufacturer’s
instructions. The signal intensities of blots were ana-
lyzed using ‘Image J’ (National Institutes of Health)
software.
Preparation of nuclear and cytoplasmic fractions
Nuclear extracts were prepared according to a method
published previously [22]. Briefly, the cells in dishes
were washed with PBS. Cells were then scraped, trans-
ferred to microtubes, and allowed to swell after the
addition of 100 μl of hypotonic buffer containing 10
mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 2
mM dithiothreitol (DTT), and 0.5 mM phenylmethylsul-
fonylfluoride. The lysates were incubated for 10 min in
ice and centrifuged at 7,200 g for 5 min at 4°C. Super-
natants were used as cytoplasmic fractions. After wash-
ing, pellets containing crude nuclei were resuspended in
50 μl of extraction buffer containing 20 mM HEPES, pH
7.9, 400 mM NaCl, 1 mM EDTA, 10 mM dithiothreitol,
and 1 mM phenylmethylsulfonylfluoride and then incu-
bated for 1 hour in ice. The samples were centrifuged at
12,000 g for 10 min to obtain supernatants containing
nuclear fractions.
The association of Bcl-xL promoter region with NF-B:
Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis for the Bcl-xL promoter region was per-
formed based on the method previously described [23].
NPCs were treated with VPA and 8 hours later, cells
were washed with PBS. NPCs were prepared and cross-
linked with 1% formaldehyde for 20 min at room tem-
perature. Then formaldehyde was quenched with 125
mM glycine for 5 min at room temperature. Cells were
scraped and collected by centrifugation (2,000 g for 5
min at 4°C), then washed twice with cold PBS. Pellets
were resuspended with lysis buffer and centrifuged sev-
eral times at 12,000 g for 1 min at 4°C and the superna-
tant was removed. The nuclear pellet was washed with 1
ml lysis buffer, by resuspending the pellet, followed by
centrifugation. To shear the chromatin, the washed pel-
let was sonicated after resuspended in 1 ml of lysis buf-
fer. The lysates were cleared by centrifuging at 12,000 g
for 10 min at 4°C and the supernatants were retained.
For IP, an antibody against NF-B p65 was added to
samples and the tube was rotated for 12 hours at 4°C.
For mock IP, we incubated samples with beads without
antibody. The precipitated chromatin was cleared by
centrifugation at 12,000 g for 10 min at 4°C and the top
90% of cleared chromatin was transferred to a tube with
protein A-agarose slurry and the tubes were rotated at
4°C for 45 min on a rotating platform. The slurry was
washed at 2,000 g for few seconds and the supernatant
was removed. The beads was washed 5 times with 1 ml
cold lysis buffer then, 100 μl of 10% Chelex 100 slurry
was directly added to the washed beads and boiled for
10 min. After centrifugation at 12,000 g for 1 min of 4°
C, supernatants were transferred to a new tube. PCR
amplification was carried out for 34 cycles, and PCR
products were separated on 1.5% agarose gels. The PCR
amplification was performed for 34 cycles (94°C, 0.5
min; 57°C, 0.5 min; 72°C, 1 min) with the following oli-
gonucleotide primer sets and analyzed by DND gel
electrophoresis:
For Bcl-XL
Forward primer: 5’-GGGAGTGGTCTTTCCGAA-3’
Reverse primer: 5’-CTCCATCGACCAGATCGA-3’
RT-PCR
NPCs were treated with VPA and 2 hours later, cells
were washed with PBS and total RNA was isolated from
NPCs using Trizol reagent (Invitrogen) and 1 μg of total
RNA was converted to cDNA using Superscript II
reverse transcriptase according to the manufacturer’s
recommendation (Invitrogen). The PCR amplification
was performed for 34 cycles (94°C, 0.5 min; 57°C, 0.5
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primer sets:
For Bcl-XL
Forward primer: 5’-CCCCAGGACTTTGTACCTCA-3’
Reverse primer: 5’-TCCGAACGGTAAATGCCTAC-3’
For H,
Forward primer: 5’-TCCCTCAAGATTGTCAGCAA-3’
Reverse primer: 5’-AGATCCACAACGGATACATT-3’
Immunocytochemistry (ICC)
NPCs were treated with VPA and 8 hours later, cultured
NPCs on cover glasses (Fisher Scientific, Pittsburgh, PA)
were washed and fixed with 4% paraformaldehyde at 37°
C for 20 min. The cells were treated with 0.3% Triton
X-100 for 10 min and blocked for 30 min with blocking
buffer (1% BSA in PBS) at room temperature. The cells
were incubated overnight at 4°C with primary antibodies
against NF-B p65 (1:500), IBa (1:500), Bcl-XL (1:500),
Bax (1:500), nestin (1:500, Millipore, Billerica, MA), and
COX4 (a marker for mitochondria, 1:500, Cell Signaling,
Danvers, MA) and washed with PBS for three times
(0.1% BSA, 0.5% FBS in PBS). Secondary antibodies con-
jugated with either Rhodamine (1:500) or FITC (1:500),
were diluted in blocking buffer and incubated for 2 h at
room temperature. At this time DNA marker DAPI was
also added to blocking buffer. After 3 washes with PBS,
the cover glasses were mounted in mounting medium
(Biomeda, Foster City, CA) and viewed with a fluores-
cence microscope. (Carl Zeiss, Germany).
Statistical analysis
Data were expressed as the mean ± standard error of
mean (S.E.M) and analyzed for statistical significance
using one way analysis of variance (ANOVA) followed
by Newman-Keuls test as a post hoc test and a P value
< 0.05 was considered significant.
Results
VPA reduced NPCs cell death
We first investigated whether VPA protects cultured
NPCs from cell death. To induce cell death by with-
drawing growth factors, we changed medium with fresh
DMEM/F12 without growth factors. VPA (0.2 or 0.5
mM) was added at the time of media change. To induce
stimulated cell death, 100 nM staurosporine or 100 μM
H2O2 was also added to NPCs at 1 hour after VPA
treatment in some cases. Cells were trypsinized and
stained with PI solution 8 hr after media change. After
growth factor deprivation, approximately 14% of NPCs
showed shrinked morphology and was positive to PI. In
FACS analysis, the ratio of PI positive dead cell was
increased by staurosporine or H2O2 treatment. 0.2 and
0.5 mM of VPA decreased cell death in basal condition
as well as staurosporine- or H2O2 -stimulated conditions
(Figure 1A, B). To visualize the protective effect of VPA,
we stained NPCs with PI solution, which gave similar
results as FACS analysis (Figure 1C, D). In this
condition, staurosporine and H2O2 didn’t change either
NF-B expression or translocation to nucleus (data not
shown).
Valproic acid induced Bcl-XL expression via NF-B
signaling pathway
To determine the molecular mechanism of VPA-
induced suppression of NPCs death, we investigate Bcl-
XL and NF-B signaling pathway. Bcl-XL is a well
known anti-apoptotic molecule and highly expressed in
NPCs as well as in brain during developmental period.
We first investigated whether VPA changes the expres-
sion level of Bcl-XL in NPCs. VPA (0.2 mM and 0.5
mM) increased Bcl-XL protein and mRNA expression in
a concentration-dependent manner in Western blot
(Figure 2A, B), immunocytochemistry (Figure 2C) and
RT-PCR (Figure 2D), respectively. VPA also increased
Bcl-XL expression and inhibited PARP-1 cleavage and
caspase-3 activation induced by staurosporine or H2O2
(Figure 3).
Next, we investigated the involvement of NF-Bs i g -
naling pathway. It was previously reported that NF-B
activation drives Bcl-XL promoter to increase the pro-
tein expression in hippocampal CA1 cells [24]. NF-B
pathway affects myriad of cellular responses including
cell death and survival, which is mediated at least in
part by the regulation of the expression of Bcl-XL. We
hypothesized that VPA regulates NF-B signaling path-
way, subsequently increases expression of Bcl-XL.
Although VPA did not affect the expression levels of
NF-Bp 6 5a n dN F - B p50, it decreased the level of
IBa, a biological inhibitor of NF-B( F i g u r e4 A ,B ) .
The decreased level of IBa was also confirmed by
immunocytochemistry (Figure 4C). To determine
whether the decreased level of IBa mediates the activa-
tion of NF-B pathway, we investigated the nuclear
translocation of NF-B by performing Western blot of
cytoplasmic and nuclear fraction of NPCs culture.
Although the level of NF-B in cytoplasmic fraction
remains constant, NF-B level in nuclear fraction was
significantly increased. (Figure 5A, B) In addition, a lot
of NF-B immunoreactivity was localized in nucleus
which was co-stained with DAPI in VPA group, whereas
almost all the NF-B immunoreactivity was localized in
cytosplasm in control group (Figure 5C). Furthermore, 1
hour pretreatment of 10 μM of TDZD-8, a NF-Bi n h i -
bitor, suppressed VPA induced NF-B p65nuclear trans-
location and Bcl-XL expression (Figure 5D, E). To
unequivocally demonstrate the role of NF-B pathway
on VPA-induced Bcl-XL expression, we performed ChIP
assay. VPA significantly increased interaction between
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Page 4 of 13Figure 1 Inhibition of basal, staurosporine- or hydrogen peroxide-induced cell death of NPCs by VPA. NPCs culture were treated with 0.2
mM or 0.5 mM VPA or PBS (Vehicle) and stimulated with 100 nM staurosporine or 100 μMH 2O2. Cells were analyzed by FACS analysis or PI
staining 8 hr after the treatment as described in materials and methods. (A) The ratios of apoptotic cells were measured by FACS analysis after PI
staining. (B) Quantification of FACS data (n = 3). (C) PI cytochemical staining. VPA decreased the number of PI positive cells. (D) Quantification of
PI staining data (n = 6), Results are mean ± S.E.M. **P < 0.01 and ***P < 0.001 vs. Vehicle. ## p < 0.01, ### p < 0.001 vs. control. Scale bar
represents 100 μm.
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Page 5 of 13Figure 2 Increased expression of Bcl-XL in NPCs by VPA. (A) Bcl-XL expression was measured by Western blot after VPA treatment. VPA
significantly increased Bcl-XL expression in a concentration dependent manner. Levels of b-actin were used as control, which was not different
among groups. (B) Densitometric quantification of Bcl-XL expressions (n = 5). (C) Immunocytochemical staining of Bcl-XL expression in NPCs. Left,
NPCs were stained with Bcl-XL. Middle, NPCs were stained with nestin, a marker of NPCs. Right, Bcl-XL, nestin, and DAPI stained fields were merged.
(D) Bcl-XL mRNA expressions in NPCs were measured using RT-PCR. GAPDH was used as control. Results are mean ± S.E.M (n = 5). **P < 0.01 vs.
control. Scale bar represents 50 μm.
Figure 3 VPA increased Bcl-XL expression and decreased PARP and caspase-3 cleavage in staurosporine- or H2O2 -stimulated NPCs.
The level of PARP-1, caspase-3 and Bcl-XL was determined by Western blot. VPA increased Bcl-XL expression and suppressed PARP-1 and
caspase-3 cleavage induced by staurosporine or H2O2 in NPCs culture.
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Page 6 of 13NF-B p65 and Bcl-XL promoter region (Figure 6A, B).
These results suggest that VPA activates NF-Bb y
reducing the level of IBa, which may up-regulate Bcl-
XL expression to inhibit apoptosis of NPCs. Because
VPA may triggers ERK phosphorylation [15], we tried to
examine ERK activation by VPA, however, we did not
observe consistent increase in ERK activation by VPA
(data not shown).
VPA induces Bcl-XL expression in developing rat brain
We injected 400 mg/kg of VPA or normal saline to
pregnant rat at E12 to investigate whether VPA inhibits
cell death in vivo. Although the level of PARP-1 clea-
vage in embryonic cortex was not significantly changed
at E14, it was decreased at E16 by VPA injection. Simi-
lar to in vitro results, the level of IBa was markedly
decreased, whereas that of Bcl-XL was significantly
increased at E16 (Figure 7A, B). The expression of Bcl-
XL mRNA was also increased in E14 and E16 brain of
VPA injected rats (Figure 7C). The effect of single injec-
tion of VPA was not sustainable and no other definite
changes of PARP-1 cleavage, IBa or Bcl-XL were
detected at E18 and postnatal day 2 (data not shown).
These results suggest that prenatal exposure to VPA
may reduce the physiological apoptotic cell death of
NPCs in vivo by mechanism involving degradation of
IBa and overexpression of Bcl-XL.
VPA suppressed Bax expression in cultured NPCs and
developing rat brain
VPA regulated not only anti-apoptotic Bcl-XL expres-
sion, but also down-regulated pro-apoptotic Bax expres-
sions both in cultured NPCs (Figure 8A, B) and in
developing rat brains (E14 and E16, Figure 8C), which
inhibits Bcl-XL by hetero-dimerizing with Bcl-XL [25].
Double immunostaining result of NPCs with antibodies
against Bax and COX4, a marker of mitochondria,
showed that the expression of Bax in COX4 positive
mitochondria was also decreased as was the case in
cytosol. The up-regulation of Bcl-XL with concomitant
down-regulation of Bax by VPA may facilitate the inhi-
bition of apoptotic cell death of NPCs.
Figure 4 VPA decreased the level of IB. (A) The level of NF-B p65, NF-B p50 and IBa were measured by Western blot. (B) Densitometric
quantification of the level of IBa (n = 7). (C) Immunocytochemical staining of IBa in NPCs. NPCs were stained with an antibody against IBa
and co-stained with DAPI. Results are mean ± S.E.M. **P < 0.01 and ***P < 0.001 vs. control. Scale bar represents 50 μm.
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Activation of NF-B signaling pathway by VPA
In this study, down-regulation of IBa by VPA
mediated the activation of NF-B as evidenced by
increased translocation of p65 and p50 to nucleus. In
the canonical NF-B activation pathway, an IKK com-
plex composed of IKKa, IKKb, and IKKg phosphorylates
IB, leading to its degradation and the activation of NF-
B [26]. Many studies have reported evidences directly
implicating the involvement of NF-B/Rel family of
transcription factors in the control of apoptosis in the
immune and nervous systems. For example, NF-B
p65-/- double knockout mice demonstrated embryonic
lethality because of massive apoptosis [27].
Figure 5 VPA increased nuclear translocation of NF-B. (A) Nuclear translocation of NF-B by VPA. NPCs cellular proteins were fractionated
into nucleus and cytoplasmic fraction as described in materials and methods. The levels of NF-B in each fraction were measured by Western
blot. The level of NF-B in nucleus was increased, whereas that in cytoplasm was not changed. (B) Densitometric quantification of NF-B p65
and NF-B p50 in nuclear fraction (n = 3). (C) Translocation of NF-B p65 was confirmed by immuncytochemical staining. NPCs were co-stained
with NF-B p65 and DAPI. Arrows indicate nuclear localization of NF-B p65. (D, E) An inhibitor of NF-B, TDZD-8, was pre-treated 1 hour before
VPA treatment and nuclear translocation of NF-B p65 and Bcl-XL expression was determined as above (n = 3). Results are mean ± S.E.M. **P <
0.01 and ***P < 0.001 vs. control. Scale bar represents 50 μm.
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activation is not only involved in the nervous system
response to injury or inflammation, but also in neuro-
nal survival in developing brain as well as in the adult
nervous system. Although many studies suggested that
VPA down-regulates NF-B activity possibly via
increase in acetylation on NF-B, which may contri-
bute to the anti-inflammatory effects of VPA in ner-
vous system [28-30], at least one study suggested that
VPA protects neuron from oxidative stress-induced
cell death by acetylation-induced activation of NF-B,
although it’s still possible that inhibition of JNK activ-
ity mediates the observed protective effects of VPA
[31]. Similar pro-survival role of VPA has been
reported in hippocampal NPCs [32]. In addition to
above reports, we provide here new mechanism for the
regulation of NF-B pathway by VPA, i.e. the down-
regulation of IB. The different effects of VPA on the
regulation of NF-B activity in different experimental
conditions suggest that the regulatory effects of VPA
may differ in the context of dosing and time window
of treatment in different cell types.
Figure 6 Increased association of NF-B with Bcl-XL gene promoter in response to VPA. The association of NF-B with Bcl-XL promoter
was analyzed as described in materials and methods. (A) ChIP identifies the association of Bcl-XL promoter by NF-B transcription factor. VPA
significantly increased binding of NF-B with Bcl-XL promoter region. (B) Densitometric quantification of ChIP assay (n = 3). Results are mean ±
S.E.M. **P < 0.01 and ***P < 0.001 vs. control.
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lates IB is not clear. Although the transcriptional or
translational down-regulation of IB is also possible, one
interesting hypothesis is the rapid degradation of IBb y
VPA, especially considering the rapid degradation of IB
by proteasomal pathway (for a review, see [33]). In fact,
VPA induced the proteasomal degradation of HDAC2,
which might be regulated by the induction of E2 ubiquitin
conjugase Ubc8 and increased ubuiquitination [34]. The
concentration of VPA (0.2-0.5 mM) used in this study is
similar with the concentration of VPA required for the
reduction of HDAC2 protein levels as well as that required
for inhibition of HDAC enzymatic activity. In our experi-
ment, we also observed that 0.2 or 0.5 mM VPA strongly
increased histone acetylation in NPCs, which may suggest
that the concentration of VPA used in this study might be
in the range of HDAC inhibitory concentration as well as
that required for the regulation of ubiquitination-depen-
dent HDAC degradation. In other study, VPA decreased
steroid secretion by increasing the ubiquitination and
degradation of SF-1 in similar dose ranges [35]. Although
the ubiquitination dependent regulation of key regulatory
molecules in NPCs by VPA is an emerging area of investi-
gation, which we hope to explore further using a series of
biochemical and molecular biological tools in the future,
these results suggest that VPA might regulate the ubiquiti-
nation and degradation of signaling molecules in a clini-
cally relevant concentration r. Alternatively, VPA may
induce the phosphorylation of IB for its degradation
through the activation of PI3K-Akt-GSK3b pathways or
ERK 1/2 pathways, the two well known target pathways
regulated by VPA. Those two possibilities are now under
active investigation in this laboratory.
Regulation of the expression of anti-apoptotic protein
Bcl-XL by VPA
Although Bcl-2 is the prototype of anti-apoptotic pro-
tein and is extensively studied so far, Bcl-2 levels
decline rapidly during development [36] and targeted
disruption of Bcl-2 resulted in only subtle
Figure 7 VPA up-regulates Bcl-XL expression and inhibits cell death in vivo. VPA was injected into pregnant rats at E12 and embryonic
whole brain lysates of control and VPA group at each embryonic day (E14 and E16) were obtained as described in materials and methods. (A)
Western blot of apoptotic markers PARP-1 cleavage was reduced in VPA model at E16. IBa level was decreased and Bcl-XL expression was
increased in VPA group at E16. (B) Densitometric quantification of IBa (n = 5) and Bcl-XL. (n = 7) (C) Bcl-XL mRNA level was measure by RT-
PCR, which was increased at E14 and E16. Results are mean ± S.E.M. ***P < 0.001 vs. control.
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vations suggest that other Bcl-2 family members may
p l a yam o r es i g n i f i c a n tr o l ei nt h ed e v e l o p m e n to f
embryonic brain. Bcl-XL is another anti-apoptotic Bcl-
2 family member which is expressed at relatively high
levels in the nervous system [38,39]. In contrast to
Bcl-2, high levels of Bcl-XL are maintained throughout
development into adulthood [36,38-40] and the Bcl-
XL-/- mice die during embryonic period [36] with
extensive apoptotic cell death in the developing ner-
vous system [41]. In our experiment, VPA up-regu-
lated Bcl-XL expression and inhibited NPCs cell death
in basal condition as well as pro-apoptotic condition
induced by staurosporine and H2O2.
VPA induced abnormality in cell death during
development may implicates the underlying mechanism
of hyperneurogenesis in some developmental disorders
In our study, VPA inhibited apoptotic cell death of
NPCs. The decreased apoptosis may contribute to the
increased NPCs resulting in hyper-differentiation of
neuron in VPA-treated subjects. VPA is a potent tera-
togen and causes behavioral and neuroanatomical
abnormalities similar to those seen in autism [42-45].
Interestingly, one of the anatomical feature observed in
autism patients is macrocephaly and increased neuron
density [46,47]. Prenatal VPA exposure model is one
of the most widely used animal model for autism [43].
These results suggest that exposure to VPA during
developmentally critical periods may contribute to the
anatomical abnormalities similar to autism, possibly via
increased NF-B activation and decreased apoptotic
cell death. Although it is also possible that increased
proliferation of NPCs may lead to increased neuronal
density, which is under active investigation in our lab,
the involvement of similar mechanism, i.e. decreased
apoptotic cell death, in other neurodevelopmental dis-
orders such as tuberous sclerosis and Cowden syn-
drome would be an intriguing topic to be resolved in
the future study.
Figure 8 VPA suppressed Bax expression both in vitro and in vivo. (A) Bax expression was measured by Western blot. VPA reduced Bax
expression in cultured NPCs. (B) The reduction of Bax expression was confirmed by immunocytochemical staining. Left, NPCs were stained with
Bax. Middle, NPCs were stained with COX4, a marker of mitochondria. Right, merged image of Bax and COX4 staining. (C) VPA was injected into
pregnant rats at E12 and Bax level in embryonic brain was determined at E14 and E16. The level of Bax in brain was decreased at both time
points. Scale bar represents 10 μm.
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cal relevance of the concentration of VPA used in this
study. In many studies, 0.2 - 2 mM of VPA was gener-
ally used in neuron [48] as well as neural stem cell [49],
which is higher than the VPA concentration used in this
study (0.2-0.5 mM) without any immediate toxicity
[50,51]. The concentration of VPA used in our in vitro
study (0.2 mM or 0.5 mM) corresponds to 28.8 μg/mL
or 72.1 μg/mL, which is slightly higher but well within
the clinical concentration of VPA. In an animal model
of autism, 400 mg/kg or 600 mg/kg of VPA was routi-
nely used to mimic the human VPA exposure during
pregnancy [43]. Serum or plasma VPA concentrations
are generally in a range of 20-100 μg/mL during con-
trolled therapy against epilepsy or bipolar disorder, with
free concentration of VPA in blood and brain ranging
from 7% to 28% of the total levels. In rats treated with
400 mg/kg VPA may have blood VPA concentration of
30-50 μg/mL [52] and the concentration of VPA in
brain was one fifth of blood concentration [53]. In this
regard, VPA concentration of brain in 400 mg/kg VPA
injected animal may be calculated to approximately 6-10
μg/mL, similar to clinical VPA concentration of human
brain (7.5 - 20.8 μg/mL).
Conclusion
In this study, we provided evidences suggesting that
VPA can suppress cell death of NPCs via regulation of
NF-B pathway and Bcl-XL expression. Prenatal expo-
sure to valproic acid produces neurodevelopmental and
somatic abnormalities collectively called fetal valproate
syndrome, which includes the behavioral and anatomical
symptoms similar to those seen in autism [42,45]. Defin-
ing the role of the diminished apoptotic cell death by
exposure to VPA during developmentally critical period
on the manifestation of the anatomical and behavioral
defects would provide more insights into the pathogen-
esis of the neurodevelopmental disorders.
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